<p>Orchestra BioMed Holdings, Inc.（纳斯达克代码：OBIO - 获取免费报告）的股票在目前覆盖该公司的六家评级机构中获得了 “适度买入” 的平均推荐，Marketbeat Ratings 报告称。一位投资分析师对该股票给予了卖出评级，一位给予了持有评级，三位给予了买入评级，还有一位给予了强烈买入评级。在过去一年中，发布报告的经纪公司对该股票的平均一年目标价为 13.25 美元。</p>
<p>多家研究公司最近对 OBIO 进行了评论。巴克莱在 11 月 12 日的报告中将 Orchestra BioMed 的股票目标价从 12.00 美元下调至 11.00 美元，并对该股票给予了 “增持” 评级。Weiss Ratings 在 10 月 8 日的报告中重申了对 Orchestra BioMed 的 “卖出（e+）” 评级。HC Wainwright 在 9 月 4 日的报告中将 Orchestra BioMed 的目标价从 12.00 美元下调至 10.00 美元，并对该公司给予了 “买入” 评级。Chardan Capital 在 11 月 13 日的研究报告中重申了 “买入” 评级，并将 Orchestra BioMed 的目标价设定为 20.00 美元。最后，BTIG Research 在 8 月 20 日的研究报告中重申了对 Orchestra BioMed 的 “中性” 评级。</p>
<p>获取 <strong>Orchestra BioMed</strong> 的提醒：</p>
<p><strong>查看我们关于 OBIO 的最新报告</strong></p>
<h2>对 Orchestra BioMed 的对冲基金看法</h2>
<p>多家对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Citadel Advisors LLC 在第三季度将其在 Orchestra BioMed 的持股增加了 9.2%。Citadel Advisors LLC 目前拥有 54,002 股该公司的股票，价值 134,000 美元，此前在上个季度又购买了 4,561 股。美国银行在第二季度将其在 Orchestra BioMed 的持股增加了 35.7%。美国银行目前拥有 21,577 股该公司的股票，价值 58,000 美元，此前在上个季度又购买了 5,678 股。德意志银行在第一季度将其在 Orchestra BioMed 的持股增加了 67.3%。德意志银行目前拥有 20,219 股该公司的股票，价值 87,000 美元，此前在上个季度又购买了 8,134 股。Catalyst Funds Management Pty Ltd 在第二季度购买了 Orchestra BioMed 的新头寸，价值约 31,000 美元。最后，Creative Planning 在第二季度购买了 Orchestra BioMed 的新头寸，价值约 40,000 美元。机构投资者和对冲基金持有该公司 53.20% 的股票。</p>
<h2>Orchestra BioMed 股票下跌 0.2%</h2>
<p>Orchestra BioMed 的股票在周二开盘时为 4.39 美元。该股票的 50 日移动平均价为 3.93 美元，200 日移动平均价为 3.23 美元。Orchestra BioMed 的 12 个月低点为 2.20 美元，12 个月高点为 6.30 美元。该股票的市值为 2.479 亿美金，市盈率为-2.41，贝塔值为 0.62。该公司的流动比率为 4.73，速动比率为 4.72，债务与股本比率为 0.32。</p>
<p>Orchestra BioMed（纳斯达克代码：OBIO - 获取免费报告）在 11 月 10 日公布了其季度财报。该公司报告的每股收益（EPS）为-0.40 美元，低于市场共识预期的-0.38 美元，差距为-0.02 美元。Orchestra BioMed 的股本回报率为-320.09%，净利润率为-2,665.05%。该公司在本季度的收入为 86 万美元，而分析师预期为 74 万美元。整体来看，研究分析师预计 Orchestra BioMed 在本年度的每股收益将为-1.66 美元。</p>
<h2>Orchestra BioMed 公司简介</h2>
<p>（获取免费报告）</p>
<p>Orchestra BioMed Holdings, Inc.是一家生物医学创新公司。该公司的旗舰产品候选包括用于治疗高血压（HTN）的 BackBeat 心脏神经调节疗法（CNT）；以及用于治疗动脉粥样硬化性动脉疾病的 Virtue Sirolimus 血管灌注气囊（SAB）。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Orchestra BioMed</li>
<li>股息贵族名单中的最佳：通过贵族指数积累财富</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的启示</li>
<li>股票行业对成功投资的重要性</li>
<li>2026 年最有可能拆分的三只股票</li>
<li>股票平均计算器</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次充满活力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Orchestra BioMed 吗？</h2>
<p>在你考虑投资 Orchestra BioMed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Orchestra BioMed 并不在名单上。</p>
<p>虽然 Orchestra BioMed 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OBIO

<p>Orchestra BioMed Holdings, Inc.（纳斯达克代码：OBIO）获得了六位分析师的 “适度买入” 评级。该股票的平均一年目标价格为 13.25 美元。最近的分析师报告显示评级不一，部分价格目标被下调。机构投资者已调整其持股比例，目前该股票的市值为 4.39 美元。公司报告了季度亏损，未能达到盈利预期，且股本回报率和净利润率均为负值。Orchestra BioMed 专注于生物医学创新，包括高血压和动脉疾病的治疗</p>

<p>Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) have been given an average recommendation of &#34;Moderate Buy&#34; by the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $13.25.</p>
<div class="lb-trans"><p>Orchestra BioMed Holdings, Inc.（纳斯达克代码：OBIO - 获取免费报告）的股票在目前覆盖该公司的六家评级机构中获得了 “适度买入” 的平均推荐，Marketbeat Ratings 报告称。一位投资分析师对该股票给予了卖出评级，一位给予了持有评级，三位给予了买入评级，还有一位给予了强烈买入评级。在过去一年中，发布报告的经纪公司对该股票的平均一年目标价为 13.25 美元。</p>
</div><p>A number of research firms recently commented on OBIO. Barclays decreased their price objective on shares of Orchestra BioMed from $12.00 to $11.00 and set an &#34;overweight&#34; rating on the stock in a report on Wednesday, November 12th. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Orchestra BioMed in a report on Wednesday, October 8th. HC Wainwright reduced their price objective on Orchestra BioMed from $12.00 to $10.00 and set a &#34;buy&#34; rating for the company in a report on Thursday, September 4th. Chardan Capital reiterated a &#34;buy&#34; rating and set a $20.00 target price on shares of Orchestra BioMed in a research report on Thursday, November 13th. Finally, BTIG Research restated a &#34;neutral&#34; rating on shares of Orchestra BioMed in a research report on Wednesday, August 20th.</p>
<div class="lb-trans"><p>多家研究公司最近对 OBIO 进行了评论。巴克莱在 11 月 12 日的报告中将 Orchestra BioMed 的股票目标价从 12.00 美元下调至 11.00 美元，并对该股票给予了 “增持” 评级。Weiss Ratings 在 10 月 8 日的报告中重申了对 Orchestra BioMed 的 “卖出（e+）” 评级。HC Wainwright 在 9 月 4 日的报告中将 Orchestra BioMed 的目标价从 12.00 美元下调至 10.00 美元，并对该公司给予了 “买入” 评级。Chardan Capital 在 11 月 13 日的研究报告中重申了 “买入” 评级，并将 Orchestra BioMed 的目标价设定为 20.00 美元。最后，BTIG Research 在 8 月 20 日的研究报告中重申了对 Orchestra BioMed 的 “中性” 评级。</p>
</div><p>Get <strong>Orchestra BioMed</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Orchestra BioMed</strong> 的提醒：</p>
</div><p><strong>View Our Latest Report on OBIO</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 OBIO 的最新报告</strong></p>
</div><h2>Hedge Funds Weigh In On Orchestra BioMed</h2>
<div class="lb-trans"><h2>对 Orchestra BioMed 的对冲基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC lifted its position in shares of Orchestra BioMed by 9.2% in the third quarter. Citadel Advisors LLC now owns 54,002 shares of the company's stock valued at $134,000 after acquiring an additional 4,561 shares in the last quarter. Bank of America Corp DE increased its position in Orchestra BioMed by 35.7% during the 2nd quarter. Bank of America Corp DE now owns 21,577 shares of the company's stock worth $58,000 after purchasing an additional 5,678 shares in the last quarter. Deutsche Bank AG raised its stake in Orchestra BioMed by 67.3% in the 1st quarter. Deutsche Bank AG now owns 20,219 shares of the company's stock valued at $87,000 after purchasing an additional 8,134 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new position in Orchestra BioMed in the 2nd quarter valued at about $31,000. Finally, Creative Planning purchased a new position in Orchestra BioMed in the 2nd quarter valued at about $40,000. Institutional investors and hedge funds own 53.20% of the company's stock.</p>
<div class="lb-trans"><p>多家对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Citadel Advisors LLC 在第三季度将其在 Orchestra BioMed 的持股增加了 9.2%。Citadel Advisors LLC 目前拥有 54,002 股该公司的股票，价值 134,000 美元，此前在上个季度又购买了 4,561 股。美国银行在第二季度将其在 Orchestra BioMed 的持股增加了 35.7%。美国银行目前拥有 21,577 股该公司的股票，价值 58,000 美元，此前在上个季度又购买了 5,678 股。德意志银行在第一季度将其在 Orchestra BioMed 的持股增加了 67.3%。德意志银行目前拥有 20,219 股该公司的股票，价值 87,000 美元，此前在上个季度又购买了 8,134 股。Catalyst Funds Management Pty Ltd 在第二季度购买了 Orchestra BioMed 的新头寸，价值约 31,000 美元。最后，Creative Planning 在第二季度购买了 Orchestra BioMed 的新头寸，价值约 40,000 美元。机构投资者和对冲基金持有该公司 53.20% 的股票。</p>
</div><h2>Orchestra BioMed Stock Down 0.2%</h2>
<div class="lb-trans"><h2>Orchestra BioMed 股票下跌 0.2%</h2>
</div><p>Orchestra BioMed stock opened at $4.39 on Tuesday. The stock has a 50 day moving average of $3.93 and a two-hundred day moving average of $3.23. Orchestra BioMed has a twelve month low of $2.20 and a twelve month high of $6.30. The stock has a market capitalization of $247.90 million, a price-to-earnings ratio of -2.41 and a beta of 0.62. The company has a current ratio of 4.73, a quick ratio of 4.72 and a debt-to-equity ratio of 0.32.</p>
<div class="lb-trans"><p>Orchestra BioMed 的股票在周二开盘时为 4.39 美元。该股票的 50 日移动平均价为 3.93 美元，200 日移动平均价为 3.23 美元。Orchestra BioMed 的 12 个月低点为 2.20 美元，12 个月高点为 6.30 美元。该股票的市值为 2.479 亿美金，市盈率为-2.41，贝塔值为 0.62。该公司的流动比率为 4.73，速动比率为 4.72，债务与股本比率为 0.32。</p>
</div><p>Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Orchestra BioMed had a negative return on equity of 320.09% and a negative net margin of 2,665.05%.The firm had revenue of $0.86 million for the quarter, compared to analysts' expectations of $0.74 million. As a group, research analysts expect that Orchestra BioMed will post -1.66 earnings per share for the current year.</p>
<div class="lb-trans"><p>Orchestra BioMed（纳斯达克代码：OBIO - 获取免费报告）在 11 月 10 日公布了其季度财报。该公司报告的每股收益（EPS）为-0.40 美元，低于市场共识预期的-0.38 美元，差距为-0.02 美元。Orchestra BioMed 的股本回报率为-320.09%，净利润率为-2,665.05%。该公司在本季度的收入为 86 万美元，而分析师预期为 74 万美元。整体来看，研究分析师预计 Orchestra BioMed 在本年度的每股收益将为-1.66 美元。</p>
</div><h2>Orchestra BioMed Company Profile</h2>
<div class="lb-trans"><h2>Orchestra BioMed 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.</p>
<div class="lb-trans"><p>Orchestra BioMed Holdings, Inc.是一家生物医学创新公司。该公司的旗舰产品候选包括用于治疗高血压（HTN）的 BackBeat 心脏神经调节疗法（CNT）；以及用于治疗动脉粥样硬化性动脉疾病的 Virtue Sirolimus 血管灌注气囊（SAB）。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Orchestra BioMed</li>
<li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>Stock Average Calculator</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Orchestra BioMed</li>
<li>股息贵族名单中的最佳：通过贵族指数积累财富</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的启示</li>
<li>股票行业对成功投资的重要性</li>
<li>2026 年最有可能拆分的三只股票</li>
<li>股票平均计算器</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次充满活力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=OBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Orchestra BioMed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Orchestra BioMed 吗？</h2>
</div><p>Before you consider Orchestra BioMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Orchestra BioMed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Orchestra BioMed 并不在名单上。</p>
</div><p>While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Orchestra BioMed 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

分析师给予 Orchestra BioMed Holdings, Inc.（纳斯达克股票代码：OBIO）“适度买入” 的平均评级